Anti-ERBB2 antibody adjuvant therapy
The present application describes adjuvant therapy of nonmetastatic breast cancer using HERCEPTIN®.
1. A method of adjuvant therapy comprising administering to a human subject with nonmetastatic HER2 positive breast cancer, following definitive surgery, anthracycline/cyclophosphamide (AC) based chemotherapy, followed by sequential administration of a taxoid and trastuzumab or an antibody that blocks binding of trastuzumab to HER2.
2. The method of claim 1 , wherein the taxoid is paclitaxel or docetaxel.
3. The method of claim 2 , wherein trastuzumab is administered.
4. The method of claim 3 , wherein trastuzumab is administered at an initial dose or 4 mg/kg, followed by subsequent weekly doses of 2 mg/kg.
5. The method of claim 1 , wherein the subject has a high risk of cancer recurrence.
6. The method of claim 5 wherein the subject is less than about 50 years old.
7. The method of claim 5 wherein the subject had a tumor greater than 2 centimeters in diameter.
8. The method of claim 5 wherein the cancer is lymph node-positive.
9. The method of claim 8 wherein the subject had 4-9 involved lymph nodes.
10. The method of claim 8 wherein the subject had 10 or more involved lymph nodes.
11. The method of claim 5 wherein the subject's cancer was estrogen receptor (ER) negative.
12. The method of claim 5 wherein the subject's cancer was progesterone receptor (PG) negative.
13. The method of claim 1 , wherein the antibody is an intact, naked antibody.